The Future of Weight Management: Can New Oral Medications Solve the Regain Problem?
For millions of people, weight-loss medications like Wegovy and Mounjaro have fundamentally changed the approach to obesity. In Great Britain alone, approximately 1.6 million adults have utilized weight-loss drugs within the past year, with the vast majority accessing these treatments through private channels. However, a significant hurdle remains: the sustainability of these treatments, both in terms of cost and the tendency for patients to regain weight after stopping the medication.
The Cost Barrier and the Shift to Oral Medication
The financial burden of current injectable therapies is substantial. In the UK, a private prescription for Mounjaro can cost around £300 (NZ$680) per month. These high prices are largely driven by the complex manufacturing requirements of injectable pens and the need for cold-chain storage.
A promising development on the horizon is orforglipron (brand name: Foundayo). Unlike existing injections, orforglipron is a “small molecule” drug. Because This proves not a peptide, it can survive the digestive tract, allowing it to be taken as a daily pill. This shift in drug design significantly reduces production and storage costs. In the US, for example, a monthly supply of orforglipron is priced between US$149 and US$299 (NZ$250 – NZ$510), a notable difference compared to the over US$1,000 (NZ$1,710) often required for Mounjaro.
Clinical Trial Insights: Sustaining Weight Loss
Beyond affordability, the most critical challenge for patients is the rapid weight regain that often follows the cessation of medication. Researchers recently conducted a trial to see if switching to orforglipron could help maintain weight loss achieved through other treatments.
The study followed patients who had lost at least 5% of their body weight over 72 weeks using Wegovy or Mounjaro. After switching to either orforglipron or a placebo for 52 weeks, the results were telling:
- Mounjaro users: Those who switched to a placebo regained just over 50% of their lost weight. Those who moved to orforglipron regained only 26%.
- Wegovy users: Participants on a placebo regained 62% of their lost weight, while those on orforglipron regained 21%.
Crucially, those taking orforglipron also maintained improvements in health markers such as blood pressure, insulin, cholesterol and blood sugar levels.
What Lies Ahead
While the initial trials involved a small cohort of roughly 100 people per group, the results suggest that oral medications could provide a viable long-term strategy for weight maintenance. Orforglipron is not yet licensed for weight loss in the UK, but industry expectations suggest it could become available between late 2026 and early 2027, pending approval from the Medicines and Healthcare products Regulatory Agency.
Frequently Asked Questions (FAQ)
How does orforglipron differ from Wegovy?
Wegovy is a peptide-based injection, while orforglipron is a small-molecule pill. This makes the latter easier to store and potentially more affordable.
Why do patients regain weight after stopping these drugs?
Current studies indicate that when patients stop taking GLP-1-based medications, the health benefits—including weight loss—tend to diminish rapidly, highlighting the need for long-term maintenance strategies.
Is orforglipron more effective than Mounjaro?
Clinical trials have shown orforglipron results in just over 15% body weight loss, which is comparable to Wegovy but lower than the 21% weight loss observed with Mounjaro.
Are you navigating the complexities of weight management? Join the conversation below and share your experiences, or subscribe to our health newsletter for the latest updates on medical innovations.
